Table 1 Demographic characteristics on hepatotoxicity with HER2-targeted agents.
Characteristic | Cases, N (%) | ||||
|---|---|---|---|---|---|
Trastuzumab | T-DM1 | T-DXd | Pertuzumab | TKIs | |
Total | 1155 | 387 | 251 | 250 | 223 |
Gender | |||||
Female | 1101 (95.3%) | 376 (97.2%) | 227 (90.4%) | 246 (98.4%) | 221 (99.1%) |
Male | 54 (4.7%) | 11 (2.8%) | 24 (9.6%) | 4 (1.6%) | 2 (0.9%) |
Weight | |||||
<50 kg | 51 (4.4%) | 26 (6.7%) | 31 (12.4%) | 14 (5.6%) | 38 (17.0%) |
>100 kg | 14 (1.2%) | 6 (1.6%) | 4 (1.6%) | 1 (0.4%) | 4 (1.8%) |
50–100 kg | 447 (38.7%) | 144 (37.2%) | 86 (34.3%) | 137 (54.8%) | 74 (33.2%) |
Missing | 643 (55.7%) | 211 (54.5%) | 130 (51.8%) | 98 (39.2%) | 107 (48.0%) |
Age (years) | |||||
<18 | 2 (0.2%) | 0 (0%) | 6 (2.4%) | 0 (0%) | 0 (0%) |
>85 | 1 (0.1%) | 1 (0.3%) | 1 (0.4%) | 0 (0%) | 2 (0.9%) |
18–64.9 | 723 (62.6%) | 216 (55.8%) | 101 (40.2%) | 181 (72.4%) | 137 (61.4%) |
65–85 | 143 (12.4%) | 60 (15.5%) | 54 (21.5%) | 26 (10.4%) | 38 (17.0%) |
Missing | 286 (24.8%) | 110 (28.4%) | 89 (35.5%) | 43 (17.2%) | 46 (20.6%) |
Occupation | |||||
Physician | 639 (55.3%) | 240 (62.0%) | 161 (64.1%) | 99 (39.6%) | 126 (56.5%) |
Pharmacist | 62 (5.4%) | 36 (9.3%) | 21 (8.4%) | 13 (5.2%) | 8 (3.6%) |
Other health-professional | 87 (7.5%) | 20 (5.2%) | 0 (0%) | 8 (3.2%) | 19 (8.5%) |
Consumer | 95 (8.2%) | 55 (14.2%) | 33 (13.1%) | 20 (8.0%) | 58 (26.0%) |
Healthcare practitioner | 267 (23.1%) | 31 (8.0%) | 36 (14.3%) | 108 (43.2%) | 11 (4.9%) |
Missing | 5 (0.4%) | 5 (1.3%) | 0 (0%) | 2 (0.8%) | 1 (0.4%) |
Reporting region (Top five) | |||||
1 | China 344 (29.8%) | United States 105 (27.1%) | Japan 54 (21.5%) | China 112 (44.8%) | Japan 62 (27.8%) |
2 | United States 127 (11.0%) | Japan 38 (9.8%) | United States 50 (19.9%) | United States 29 (11.6%) | United States 53 (23.8%) |
3 | France 70 (6.1%) | Canada 33 (8.5%) | Canada 46 (18.3%) | Germany 11 (4.4%) | China 14 (6.3%) |
4 | Canada 61 (5.3%) | France 27 (7.0%) | France 42 (16.7%) | Korea 11 (4.4%) | Italy 9 (4.0%) |
5 | Japan 60 (5.2%) | Germany 22 (5.7%) | China 11 (4.4%) | Italy 10 (4.0%) | France 8 (3.6%) |
Main outcomes | |||||
Congenital Anomaly | 1 (0.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Death | 106 (9.2%) | 43 (11.1%) | 57 (22.7%) | 23 (9.2%) | 41 (18.4%) |
Disability | 9 (0.8%) | 3 (0.8%) | 0 (0%) | 2 (0.8%) | 1 (0.4%) |
Hospitalization-Initial or Prolonged | 282 (24.4%) | 102 (26.4%) | 50 (19.9%) | 83 (33.2%) | 44 (19.7%) |
Life-Threatening | 28 (2.4%) | 15 (3.9%) | 2 (0.8%) | 7 (2.8%) | 5 (2.2%) |
Other Serious (Important Medical Event) | 616 (53.3%) | 165 (42.6%) | 101 (40.2%) | 97 (38.8%) | 110 (49.3%) |
Required Intervention to Prevent Permanent Impairment/Damage | 0 (0%) | 1 (0.3%) | 1 (0.4%) | 0 (0%) | 0 (0%) |
Missing | 113 (9.8%) | 58 (15.0%) | 40 (15.9%) | 38 (15.2%) | 22 (9.9%) |
Preferred Term of Indications (Top 3) | |||||
1 | Breast cancer (959, 83.32%) | Breast cancer (330, 85.27%) | Breast cancer (191, 76.10%) | Breast cancer (231,92.40%) | Breast cancer (188,84.30%) |
2 | Gastric cancer (47, 4.08%) | Gastric cancer (1, 0.26%) | Gastric cancer (26, 10.36%) | Gastric cancer (1, 0.40%) | GC (1, 0.45%) |
3 | CC (5, 0.43%) | CC (1, 0.26%) | NSCLC (10, 3.98%) | OC (1, 0.40%) | PC (1, 0.45%) |
